Acromegaly - The Annual Endocrine Society of Australia Seminar ...

More documents

Recommendations

Info

AACE 2011 Guidelines, Katznelson et al Residual disease after TSS SSA usually first line medical therapy d , consider a DA in the setting <strong>of</strong> modest disease e , consider RT in patients with residual tumor following TSS GH antagonist utilized as next line therapy
Case 3 Macroadenoma CS involvement No chiasmal compression Surgery unlikely to be curative Surgery? Primary Medical <strong>The</strong>rapy?
Page 1 and 2: Acromegaly Endocrine Society of Aus
Page 3 and 4: Case 1 45 yo male sent to PCP beca
Page 5 and 6: MRI scan: microadenoma
Page 7 and 8: Biochemical Diagnostic Testing Ran
Page 9 and 10: Therapy Surgery is primary therape
Page 11 and 12: Post-Surgical Assessment (A) Immed
Page 13 and 14: Case 1, contd. 12 week serum IGF-1
Page 15 and 16: Case 2 48 yo female with joint pai
Page 17 and 18: Pre-operative Medical Therapy? Imp
Page 19 and 20: Peri-operative risk with acromegaly
Page 21 and 22: Therapy of Residual Disease after S
Page 23 and 24: Biochemical Monitoring on Medical T
Page 25 and 26: Medical Therapy Somatostatin Analo
Page 27 and 28: Growth Hormone Receptor Antagonist
Page 29 and 30: Case 2, contd Because of residual
Page 31 and 32: SSA resistant acromegaly: Increase
Page 33 and 34: van der Lely, Eur J Endo 2011;164:3
Page 35 and 36: Radiation Therapy: Types Conventio
Page 37: Back to case… Macroadenoma CS inv
Page 41 and 42: Additional Monitoring: Comorbiditie
Page 43 and 44: Additional Monitoring: Comorbiditie
Page 45 and 46: Pregnancy and Acromegaly Limited d
Page 47: Pregnancy and Acromegaly Once pati

Acromegaly - The Annual Endocrine Society of Australia Seminar ...

Create successful ePaper yourself

Delete template?

Save as template?